Founded in 2016 by Gilbert Bernier, Alain Rheault and Anthony Flamier, StemAxon aims to be the world leader and defined reference in R&D related to neurodegenerative diseases, mainly, sporadic Alzheimer’ disease (AD) and Macular degeneration. Strong of its results after years of research by world renowned Dr. Gilbert Bernier, StemAxon provides a new platform (PCT) for the pharmaceutical industry to test their lead compounds against AD. This unique platform greatly increases the efficiency to validate existing molecules for drug development and treatment. StemAxon has also developped a Molecular Diagnostic and target readout for AD. StemAxon is currently in the final pre-clinical phase for its Universal macular transplantation program in translational medicine. Additionally, StemAxon has created a ready kit mix with protocol, which accelerates any types of neuronal research, including neuron silicon interface. The simplicity of use of the product will enable anyone, to grow and study normal and disease-affected human neurons in vitro.